
A Maryland pathologist and MedChi past president explains how all-or-nothing contracts, anti-steering clauses and private equity deals inflate costs. He also outlines the federal and state reforms that could restore competition.
Patients are paying attention, but not all messages are true.
Vaccine development, safety and efficacy gained new heights of public attention during the COVID-19 pandemic.





